The ReCOGNITION study staff is always available to answer any questions or concerns about the study or the study drugs.
For additional information, call Anne at IPC Research, 262-513-0700.
If you or someone you care about has been diagnosed with mild Alzheimer's, learn more about the ReCOGNITION study evaluating an investigational sleep-promoting Alzheimer's disease drug.
To pre-qualify for this study, a patient must:
All study-related visits, tests, and drugs will be provided to eligible participants at no cost. In addition, reimbursement for study-related time and travel may be provided.
Before a patient can begin the study, he or she will be screened for eligibility. If the patient is determined to be eligible, and agrees to participate, he or she will be randomly assigned (like the flip of a coin) to receive one of three doses (5 mg, 20 mg, or 50 mg) of the investigational drug, or placebo. Study participants have a greater chance of receiving the investigational drug than placebo.
Study participants, the study doctor, and study staff members will not know which study drug (investigational or placebo) participants are receiving. This is to prevent any opinions about the investigational drug or placebo from affecting the results of the study. However, in the event of an emergency, this information will be provided.
Study participants will take their study drug once daily following a meal or snack, preferably between 9 pm and 11 pm. Participants will be asked to take their study drug for 26 weeks and visit the study clinic 5 times during the study. Participants will also receive weekly telephone calls from the study staff. Total study participation will last approximately 28 weeks.
Throughout the study, doctors and the study staff will evaluate the health and progress of all study participants through various tests and assessments during the clinic visits and weekly phone calls. Some of these include, but are not limited to: